



oppose summary judgment on her claim that Mentor did not adequately warn her physician of the risks of ObTape before her implant surgery. As discussed below, the Court denies Mentor's summary judgment motion as to Mrs. Luciano's pre-implant failure to warn claim (ECF No. 38 in 4:14-cv-207).

#### SUMMARY JUDGMENT STANDARD

Summary judgment may be granted only "if the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law." Fed. R. Civ. P. 56(a). In determining whether a *genuine* dispute of *material* fact exists to defeat a motion for summary judgment, the evidence is viewed in the light most favorable to the party opposing summary judgment, drawing all justifiable inferences in the opposing party's favor. *Anderson v. Liberty Lobby, Inc.*, 477 U.S. 242, 255 (1986). A fact is *material* if it is relevant or necessary to the outcome of the suit. *Id.* at 248. A factual dispute is *genuine* if the evidence would allow a reasonable jury to return a verdict for the nonmoving party. *Id.*

#### FACTUAL BACKGROUND

Viewed in the light most favorable to the Lucianos, the record reveals the following. Juana Luciano sought treatment from Dr. Stanley Kraus for stress urinary incontinence. Dr. Kraus advised Mrs. Luciano to undergo an ObTape implant procedure, and he implanted Mrs. Luciano with ObTape on June 21,

2004. Dr. Kraus does not recall receiving any literature or training regarding ObTape. Kraus Dep. 23:8-15, 36:13-22, ECF No. 39-4. Dr. Kraus could not identify any specific statements Mentor made that played a role in his decision to implant Mrs. Luciano with ObTape, and he does not recall reading the ObTape product insert data sheet. *Id.* at 36:23-3, 69:23-70:25. But Dr. Kraus did recall that he spoke with a Mentor sales representative about ObTape's pore size. *Id.* at 22:10-23:7. Although Dr. Kraus did not remember the specifics of his discussion with the Mentor representative regarding ObTape's pore size, he did understand that it was important for a mesh product to have large pores. *Id.* at 22:23-23:15. Dr. Kraus also testified that if he had known that ObTape had a greater risk of erosion (a complication associated with smaller pore size) than other slings, that information could have altered his decision to use ObTape to treat Mrs. Luciano.<sup>1</sup> *Id.* at 116:18-117:15.

---

<sup>1</sup> Mentor argued for the first time in its reply brief that the Court should ignore Dr. Kraus's testimony in response to a hypothetical question suggesting that ObTape had a higher rate of erosion than other mesh slings because Plaintiffs did not present Dr. Kraus with evidence to support the hypothetical. Based on the Court's experience, which includes presiding over three trials regarding ObTape and deciding more than 100 summary judgment motions, the Court is satisfied that the common evidence regarding ObTape is sufficient to create a genuine fact dispute on whether ObTape had smaller pores and a higher erosion rate than other mesh sling products used to treat stress urinary incontinence.

## DISCUSSION

The Lucianos filed this action in the United States District Court for the District of Massachusetts on July 8, 2014, and the Judicial Panel on Multidistrict Litigation transferred the case to this multidistrict litigation proceeding for pretrial proceedings. The parties agree that Massachusetts law applies to this case because Mrs. Luciano was a Massachusetts resident when her ObTape was implanted, and all of her ObTape-related treatment took place in Massachusetts.

Under Massachusetts law, a prescription medical device manufacturer must adequately inform a patient's physician of the foreseeable risks associated with the device. *E.g.*, *Albright v. Boston Sci. Corp.*, 58 N.E.3d 360, 368 (Mass. App. Ct. 2016). Here, Mentor argues that Mrs. Luciano cannot establish causation on her pre-implant failure to warn claim because she did not present enough evidence to show that (1) Dr. Kraus relied on any representations from Mentor when he selected ObTape for Mrs. Luciano and (2) Dr. Kraus would not have recommended ObTape for Mrs. Luciano had he received a different warning from Mentor. But, as discussed above, Mrs. Luciano pointed to evidence that Dr. Kraus discussed ObTape—including its pore size—with a Mentor representative and that if Dr. Kraus had known that ObTape had a greater risk of erosion (a complication associated with smaller pore size) than other slings, that information could have

altered his decision to use ObTape to treat Mrs. Luciano. Based on this evidence, the Court finds that there is a genuine fact dispute on Mrs. Luciano's pre-implant failure to warn claim, and Mentor's summary judgment motion on this claims is denied.

#### CONCLUSION

As discussed above, Mentor's partial summary judgment motion (ECF No. 38 in 4:14-cv-207) is granted as to Mrs. Luciano's strict liability, breach of express warranty, continuing duty to warn, and punitive damages claims. The motion is denied as to Mrs. Luciano's pre-implant failure to warn claims. That claim, along with the following claims, remain pending for trial: Mrs. Luciano's claims for negligence and breach of implied warranty and Mr. Luciano's loss of consortium claim.

#### SUGGESTION OF REMAND

This action is ready for trial. Given that Mentor has not elected to waive venue under *Lexecon Inc. v. Milberg Weiss Bershad Hynes & Lerach*, 523 U.S. 26 (1998) since Phase IV-1, the Court finds it appropriate to suggest that this action be remanded to the transferor court, the U.S. District Court for the District of Massachusetts. For the convenience of that court, the appendix to this Order contains a brief chronicle of the coordinated proceedings, as well as a list of significant filings and orders in MDL No. 2004.

The Clerk of Court is directed to provide a copy of this Order to the Clerk of the Judicial Panel on Multidistrict Litigation.

IT IS SO ORDERED, this 22nd day of February, 2017.

s/Clay D. Land

---

CLAY D. LAND

CHIEF U.S. DISTRICT COURT JUDGE  
MIDDLE DISTRICT OF GEORGIA

## APPENDIX

### I. Brief Background of the Mentor ObTape MDL

Mentor Worldwide LLC manufactured and sold a polypropylene mesh suburethral sling product called ObTape Transobturator Tape, which was used to treat women with stress urinary incontinence. The United States Food and Drug Administration cleared ObTape for sale in 2003 via its 510(k) regulatory process, and ObTape remained on the market in the United States until March 2006.

Nearly ten years ago, women who had been surgically implanted with ObTape began filing lawsuits against Mentor, alleging that they had been injured by ObTape—primarily that they suffered infections caused by ObTape and that they were injured when ObTape eroded through their bodily tissues. In December 2008, the Judicial Panel on Multidistrict Litigation created MDL No. 2004 and transferred seventeen actions involving alleged injuries resulting from ObTape to this Court for consolidated and coordinated pretrial proceedings. See *In re Mentor Corp. ObTape Transobturator Sling Products Liability Litigation*, 588 F. Supp. 2d 1374 (J.P.M.L. 2008). After pretrial proceedings and a bellwether trial that settled mid-trial, the original cases and approximately forty additional tag-along cases transferred to this Court were resolved through settlement. Since then, MDL No. 2004 has grown to include more

than 800 additional tag-along cases, more than eighty of which remain open. The litigation was divided into phases, and cases from phases IV-8 through IV-10 are still pending. In 2013, the Court tried a Phase III bellwether case to verdict. In 2016, the Court tried a Phase IV-1 bellwether case to verdict.

## II. Significant Filings in MDL No. 2004

These filings are, for the most part, evidentiary rulings that were made in the context of the bellwether cases that were tried in this Court; these issues may arise again.

1. Order Denying Motion to Disqualify Expert Witness Dr. Catherine Ortuno, Apr. 1, 2010. ECF No. 231 in 4:08-md-2004; 2010 WL 1416548.  
**Summary:** Mentor sought to exclude the testimony of Dr. Catherine Ortuno, who was an employee of a French Mentor subsidiary called Porges. While she was employed by Porges, Dr. Ortuno and a colleague developed concerns about the safety of ObTape and ultimately recommended that sales of ObTape be stopped. The Court concluded that Dr. Ortuno would be permitted to serve as an expert witness for Plaintiffs but that she would not be permitted to offer any testimony that would divulge privileged, attorney-client communications.
2. Order on Phase I Summary Judgment Motions and Admissibility of Plaintiffs' Experts, Apr. 22, 2010. ECF No. 241 in 4:08-md-2004; 711 F. Supp. 2d 1348.  
**Summary:** Mentor sought to exclude Plaintiffs' experts under Federal Rule of Evidence 702.  
**Dr. Catherine Ortuno** - motion denied; the Court found that Dr. Ortuno's methodology was sufficiently reliable.  
**General Causation Witnesses** (Dr. Linda Brubaker, Dr. Suzanne Bush, Dr. Michel Cosson, Dr. John Davis, Dr. James Hiller, Dr. Mickey Karram, Dr. Kenneth Mitchell, Dr. Donald Ostergard, Dr. William Porter, and Dr. Andrew Siegel) - motion denied; the Court found that these experts' methodology was sufficiently reliable.  
**Specific Causation Witnesses** (Dr. Linda Brubaker, Dr. Suzanne Bush, Dr. John Davis, Dr. James Hiller, Dr.

Mickey Karram, Dr. Kenneth Mitchell, and Dr. Mark Slack) - motion denied; the Court found that these experts' methodology was sufficiently reliable.

**Dr. George Samaras** - motion granted in part and denied in part; based on then-existing Rule 26 Report, the Court concluded that Dr. Samaras would be permitted to testify on general causation but not specific causation.

**Dr. Ahmed El-Ghannam** - motion denied; the Court found that Dr. El-Ghannam's opinions were sufficiently reliable.

**Dr. Paul Ducheyne** - motion granted in part and denied in part; based on then-existing Rule 26 Report, the Court concluded that Dr. Ducheyne could not testify regarding what caused degradation in ObTape but could testify that Mentor should have done more testing based on Mentor's awareness that ObTape could degrade.

**Dr. Arnold Lentnek** - motion deferred pending *Daubert* hearing. On May 12, 2010, the Court decided to permit Dr. Lentnek's testimony (ECF No. 301 in 4:08-md-2004).

3. Order re Evidence Related to FDA Regulatory Process, Apr. 23, 2010. ECF No. 242 in 4:08-md-2004; 2010 WL 1734638.

**Summary:** Plaintiffs sought to exclude evidence related to the FDA regulatory process. Discussed basic rules regarding evidence of FDA regulatory process. Deferred ruling until pretrial conference. At the pretrial conference on May 3, 2010, the Court granted the motion in limine but stated that if Plaintiffs opened the door to the FDA evidence, it could come in. (ECF No. 299 - Transcript 174:9-175:16).

**Note:** the Court admitted 510(k) evidence during the 2013 trial of *Morey v. Mentor*, 4:11-cv-5065 but gave a limiting instruction on this issue. *Morey*, Jury Instructions Charge No. 11, ECF No. 183 in 4:11-cv-5065. But the Court reconsidered its ruling on the admissibility of FDA 510(k) evidence in its order on Phase IV-1 motions in limine dated December 3, 2015.

4. Order re Phase I Plaintiffs' Experts, Apr. 27, 2010. ECF No. 246 in 4:08-md-2004; 2010 WL 1727828.

**Summary:** Mentor sought to exclude the testimony of Plaintiffs' experts under Federal Rule of Evidence 702 and based on relevance. The motion was granted in part and denied in part.

**Dr. Ann Buchholtz** - testimony not permitted.

**Rabbit Study** - testimony explaining rabbit study permitted, but not testimony that rabbit study establishes that ObTape is capable of causing similar conditions in humans.

**Mentor's Warnings to Physicians and the FDA** - testimony may be relevant to failure to warn claim, but Plaintiff must establish relevance before eliciting this testimony.

5. Order re Phase I Experts, Apr. 29, 2010. ECF No. 282 in 4:08-md-2004; 2010 WL 1782272.

**Summary:** The parties sought to exclude expert testimony of each other's experts under Federal Rule of Evidence 702. The motions were denied.

**Dr. Michael Chernick** (Plaintiffs' statistician) - testimony permitted.

**Mentor's Specific Causation Rebuttal Witnesses** (Dr. Marta Villarraga, Dr. Charles L. Secrest, Dr. A.W. Karchmer, Dr. James M. Anderson) - testimony permitted.

**Dr. Marta Villarraga** (Mentor's expert re Mentor's conduct in bringing ObTape to Market) - testimony permitted.

**Mentor's Experts regarding Pore Distribution** (Drs. Villarraga and Clevenger) - testimony permitted.

6. Phase I Bellwether Pretrial Conference Transcript (Day 1), May 3, 2010. ECF No. 299 in 4:08-md-2004. Ruled from the bench on several motions in limine.

**Significant Issues:**

◆ Cross Motions to Exclude Evidence re FDA Regulatory Process (ECF Nos. 249 & 259) - Granted. Hr'g Tr. 164:11-175:16. Written opinion on this issue December 3, 2015. See *infra* § III.18.i.

◆ Plaintiffs' Motion to Exclude "Complication Rates" (ECF Nos. 250 & 251) - Denied. Hr'g Tr. 175:20-178:19.

7. Phase I Bellwether Pretrial Conference Transcript (Day 2), May 4, 2010. ECF No. 300 in 4:08-md-2004. Ruled from the bench on several motions in limine.

**Significant Issue:**

**Mentor's Motion to Exclude Evidence Adverse Event Reports** (ECF No. 273) - Denied, but reports must be redacted. Hr'g Tr. 42:7-47:8.

8. Order re Dr. Arnold Lentnek, May 12, 2010. ECF No. 301 in 4:08-md-2004.  
**Summary:** Denied Mentor's motion to exclude Dr. Lentnek, concluding that Dr. Lentnek's methodology was sufficiently reliable.
9. Order to "Tie Up Some Loose Ends" after Pretrial Conference, May 18, 2010. ECF No. 335 in 4:08-md-2004, 2010 WL 1998166.  
**Summary:** addressed several issues. Significantly, the Court stated that it would permit recording of the testimony of European witnesses so the recordings could be used in later trials of MDL No. 2004 cases. Also addressed the trial structure and concluded that trial should be bifurcated (Phase 1: compensatory damages/punitive damages entitlement; Phase 2: punitive damages amount).  
  
**Note:** part of this Order was later vacated (see ECF 350 re continuing duty to warn under Georgia law).
10. Order re Subsequent Remedial Measure, May 20, 2010. ECF No. 341 in 4:08-md-2004, 2010 WL 2015146.  
**Summary:** Concluded that Mentor's decision to stop selling ObTape is a subsequent remedial measure under Federal Rule of Evidence 407, so evidence of this decision is not admissible "to prove negligence, culpable conduct, a defect in a product, a defect in a product's design, or a need for a warning or instruction" but may be admitted for another purpose. Also concluded that Mentor's introduction of a new sling product, Aris, was not a subsequent remedial measure under Federal Rule of Evidence 407.
11. Order re Similar Complications, May 28, 2010. ECF No. 351 in 4:08-md-2004, 2010 WL 2196632.  
**Summary:** Explained rationale for concluding that other incidents of ObTape complications proffered by Plaintiffs were substantially similar to Plaintiffs' injuries.
12. Order Appointing Plaintiffs' Liaison Counsel and Co-Lead Counsel, Sept. 21, 2011. ECF No. 422 in 4:08-md-2004.
13. Order Establishing Plaintiffs' Litigation Expense Fund and Common Benefit, Aug. 9, 2012. ECF No. 493 in

4:08-md-2004. This agreement is between Plaintiffs' counsel and addresses the sharing among Plaintiffs of the cost of special services performed and expenses performed for the common benefit of the Plaintiffs of MDL No. 2004.

14. Text Order re Dr. Ahmed El-Ghannam, June 4, 2013 in *Morey v. Mentor*, 4:11-cv-5065. Explained that general causation witness's must be tied to the Plaintiff: "To introduce [Dr. El-Ghannam'] testimony regarding ObTape degradation and/or the release of toxins, the witness must establish a causal connection between that degradation and/or release of toxins and Plaintiff's infection and extrusion/erosion."
15. Order re Post-Injury Evidence/Punitive Damages (in *Morey v. Mentor*), June 12, 2013. ECF No. 671 in 4:08-md-2004.  
**Summary:** Concluded that, under Minnesota law, certain post-injury evidence is admissible on the issue of punitive damages.
16. Order re Withdrawal of ObTape from the Market (in *Morey v. Mentor*), June 12, 2013. ECF No. 673 in 4:08-md-2004.  
**Summary:** Reiterated that the withdrawal of ObTape from the market was a subsequent remedial measure under Federal Rule of Evidence 407.
17. Jury Instructions and verdict form in *Morey v. Mentor*, June 13, 2013. ECF No. 183 in 4:11-cv-5065. **Notes:** Morey asserted a negligence claim under Minnesota law. The Court reconsidered its ruling on the admissibility of FDA 510(k) evidence in its order on Phase IV-1 motions in limine dated December 3, 2015.
18. Order on Motions in Limine, Dec. 3, 2015 (in *Taylor*, 4:12-cv-176; *Sanborn*, 4:13-cv-42; and *Mack*, 4:14-cv-117), ECF No. 92 in 4:12-cv-176, 2015 WL 7863032.

**Significant issues:**

- i. **FDA 510(k) Evidence.** Ruled that evidence of 510(k) preclearance process would not be admitted because even if it is relevant, the probative value is substantially outweighed by the risk of unfair prejudice and potential to confuse and mislead the jury.

- ii. **Dr. Lentnek.** Ruled that Plaintiffs would have to establish "fit" prior to admission of Dr. Lentnek's testimony.
  - iii. **Dr. El-Ghannam.** Ruled that Plaintiffs would have to make proffer of specific causation before Dr. El-Ghannam could testify on certain issues.
  - iv. **Post-Implant Evidence.** Ruled that evidence of Mentor's conduct and awareness after Plaintiffs' implant date is admissible.
19. Order re Similar Complications (in *Taylor*, 4:12-cv-176; *Sanborn*, 4:13-cv-42; and *Mack*, 4:14-cv-117), Feb. 1, 2016. ECF No. 115 in 4:12-cv-176, 2016 WL 393958. **Summary:** Explained rationale for concluding that other incidents of ObTape complications proffered by Plaintiffs were substantially similar to Plaintiffs' injuries.
20. Jury Instructions and verdict form in *Taylor v. Mentor*, Feb. 18, 2016. ECF Nos. 172, 174 in 4:12-cv-176. **Note:** Taylor's claims were under Florida law.